Summary
A plant derived activator of natural killer cells (NK) at 2-3 hours after the injection. It is claimed that cytolytic capacity of NK cells is increased 3-fold after activation with Immunomax. Produced and registered in Russia for use as an antiviral pharmaceutical.
It can be bought in small vials ready for injection and is administrated as an intramuscular injection.
It is claimed to work against infections caused by viruses (human papillomavirus, herpes simplex virus, parvovirus, carnivore plague virus, etc.) or bacteria (colibacillus, salmonella, staphylococcus, chlamydia, mycoplasma, ureaplasma, etc.).
We are currently using it so I will soon add here an update on the response.
A little more about this vaccine: Pan Am Cancer Treatment Center Announces Availability of ImmunoMax Natural Killer Cell Activating Immunotherapy for Advanced Cancer Patients
Mechanism
TLR-4 agonist http://www.ncbi.nlm.nih.gov/pubmed/25432242
More about impact of TLR4 modulation in cancer and TLR4 Immunomodulatory Agents http://journal.frontiersin.org/article/10.3389/fimmu.2014.00328/full
The immunopharmacological mechanisms underlying the effect of the drug are the activation of the following components of the immune system:
€“ NK cells, which intensively express CD69 activation molecules 2€“3 h after Immunomax administration;
€“ circulating monocytes, which 2€“4 h after the activation with Immunomax begin to secrete cytokines,
including interleukin-8 and interleukin-1b, and tumour necrosis factor-a;
€“ neutrophilic granulocytes, the activation of which is mediated by monocytes; the drug has no direct effect
on neutrophilic granulocytes. Interleukin-8 secreted by monocytes results in the activation of neutrophilic
granulocytes, which becomes manifest 24 h after the Immunomax administration;
€“ tissue macrophages, in which morphology is altered, the production of bactericide substances is
enhanced, and the 5′-nucleotidase activity is changed;
€“ a production of antibodies against soluble and corpuscular antigens.
http://www.gepon.ru/deutsch/data/arts/Imm_prosp_eng.pdf
Safety/Toxicity
Unknown.
Preparation & Administration
The vials have to be stored between 4 and 8 C.
The recommended dose for adults and children over 12 years of age is 100€“200 U intramuscularly once a day.
The contents of a vial (ampoule) is dissolved before use in 1 ml of water for injections and injected intramuscularly at
a dose of 100€“200 U, depending on the disease severity. The course of treatment consists of six injections on days 1,
2, 3, 8, 9, and 10 of treatment.
Source & Cost
It can be ordered from Russian pharmacies.
It can also be ordered in Germany from the following pharmacy Obstland Apotheke, Luise-Jahn-StraŸe
1, 14542 Werder/Havel, Tel. 03327-45569, Fax 03327-42858, [email protected] Ref
A box of 3 vials (each containing 200 E.U. ImmunoMax) costs about 60 euro.
Synergists & Antagonists
Naltrexone, often used in low dose (4.5mg/day) as an anti-cancer element, is an antagonist of TLR4 (Ref.) while Immunomax is a TLR-4 agonist. Indeed, it seems that while cancers such as the adrenal (ACC) is characterized by a downregulation of TLR4, in other cancers (such as lung cancer) may be overactive and may play important roles in promoting immune escape of cancer cells by inducing immunosuppressive cytokines and apoptosis resistance (Ref.) In such cases Naltrexone should be used instead of ImmunoMax. Therefore, based on the research above I would not suggest the use of Naltrexone (or LDN) in cancers such as ACC or others where TLR4 is downregulated. On this line, I would shortly check the literature on whether TLR4 is upregulated or downregulated in your case and use LDN or Immunomax depending on your case.
More about impact of TLR4 modulation in cancer and TLR4 Immunomodulatory Agents http://journal.frontiersin.org/article/10.3389/fimmu.2014.00328/full
Clinics Treating Patients with Immunomax
First clinic I heard of using it was http://cancerimmunotherapy.mx/web/pan-am-protocol/
However, anyone can use it at home.
References:
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. http://www.ncbi.nlm.nih.gov/pubmed/25432242
BACKGROUND: Previously we demonstrated that the resection of primary 4T1 tumors only slightly prolongs mouse survival, but importantly, creates a “window of opportunity” with attenuated suppressor cell and increased activated T cell populations. This suggests that additional activation of the immune system by immunostimulatory agents during this period may enhance anti-tumor immunity and potentially eradicate micro-metastatic disease in this stringent model. We hypothesized that the immunostimulator Immunomax®, which is comprised of a plant-derived polysaccharide, is non-toxic in humans and stimulates immune defense during the infectious diseases treatment, may have also anti-tumor activity and be beneficial in the adjuvant setting when endogenous anti-tumor responses are present and during the “window of opportunity” in post-resection metastatic breast cancer model. Here we provide the initial report that Immunomax® demonstrates the capacity to eliminate micro-metastatic disease in the post-resection, 4T1 mouse model of breast cancer.
METHODS: The efficacy of Immunomax® was evaluated by analyzing survival rate and the number of spontaneous clonogenic tumor cells in the lung homogenates of mice. The frequencies of activated NK, CD4(+) and CD8(+) cells as well as myeloid-derived suppressor cells and Treg cells were evaluated using flow cytometry. Highly purified mouse and human dendritic and NK cells were sorted and the effect of Immunomax® on activation status of these cells was assessed by flow cytometry. The property of Immunomax® as TLR-4 agonist was determined by NF-κB/SEAP reporter gene assay, WB, RT-PCR.
RESULTS: Immunomax® injections significantly prolonged overall survival and cured 31% of mice. This immunostimulator activates DCs via the TLR-4, which in turn stimulates tumoricidal NK cells and in vitro, completely inhibits growth of 4T1 cells. Incubation of PBMC from healthy donors with Immunomax® activates NK cells via activation of plasmacytoid DC leading significantly higher efficacy in killing of human NK-target cells K562 compared with non-treated cells.
CONCLUSION: This is the first demonstration that Immunomax® is a TLR-4 agonist and the first report of a documented role for this pharmaceutical grade immunostimulator in augmenting anti-tumor activity, suggesting that incorporation of Immunomax® into developing breast cancer therapeutic strategies may be beneficial and with less potential toxicity than checkpoint inhibitors.
Disclaimer:
This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.
